NeOnc Technologies Establishes Key Phase 2 Dose for Oral NEO212, Reports Early Anti-Tumor Activity
NTHI has more than doubled off its 52-week low of $3.2.
Summary
NeOnc Technologies has successfully completed the Phase 1 dose-escalation study for its oral cancer drug, NEO212, establishing a Recommended Phase 2 Dose (RP2D) of 610 mg. The study reached the Maximum Tolerated Dose (MTD) at 810 mg, with the RP2D set one cohort lower. Importantly, the company observed early signs of anti-tumor activity and durable disease control in heavily pretreated patients with Glioblastoma Multiforme (GBM) and brain metastases, alongside a favorable safety profile with no significant myelosuppression, hepatic, or renal toxicity. This positive Phase 1 outcome is a material de-risking event for the company's lead candidate, paving the way for further clinical development. Investors will now watch for the planned Type B FDA meeting and the initiation of Phase 2 expansion studies, which could potentially leverage accelerated approval pathways.
At the time of this announcement, NTHI was trading at $9.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $214.7M. The 52-week trading range was $3.20 to $25.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.